Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...

Two-story clinic expansion adds infusion suite, pharmacy, and exam rooms. Clinic provides multidisciplinary care for prostate, bladder, kidney, and testicular cancers. Expansion enhances clinical ...

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community ...

A surgeon who devoted his career to drive innovation in urologic cancer diagnosis and treatment will lead urology at Northwell Health. Dr. Samir Taneja, who was appointed to the position after a ...

Discover a comprehensive palliative care plan designed to enhance quality of life for those with metastatic bladder cancer.

Surveillance plays a major role in the management of men with cancer clinically confined to the testis. Both the American Urological Association (AUA) and the European Association of Urology (EAU) ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...

Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...